NextTranslate Biopharmaceutical Co., Ltd. 创始人及行政总裁
Dr. Hang Lu is the founder and CEO of NextTranslate Biopharmaceutical Co., a company focusing on the development and manufacture of mRNA- and advanced technology-based preventive and therapeutics products.
Dr. Lu has over 25 years of experience in biological product development in pharmaceutical and biotechnology industry, including Merck Co. and Emergent BioSolutions (EBSI), a NYSE-listed global life sciences company that seeks to protect and enhance life by providing specialty products including vaccines and therapeutics for civilian and military populations. Dr. Lu held roles of increasing responsibilities at EBSI over the last 20+ years, including director of CDMO Analytical Development or PAD, Principal Scientist of R&D or Nonclinical Development. He was responsible for setting up the Immunotoxicology Lab and GxP Lab and was the core team member of more than ten traditional and new generation vaccines and biologics from the discovery to preclinical and CMC development over the product life-cycle, from IND to BLA submissions leading to regulatory approvals in USA.
Dr. Lu obtained his medical degree at Zhejiang University and practiced there as a pediatric hematologist, and then completed his post-doctoral research training at the University of British Columbia with a sponsorship from the Canadian Institutes of Health Research (CIHR). Dr. Lu is an advisory committee member of Vaccine Research Council, China Association for Vaccines and was the President of the Chinese Biopharmaceutical Association (CBA, 2021-2022).